Pharmaust Limited (NUZ) Price & Analysis

Compare

28 Followers

NUZ Stock Chart & Stats

AU$0.10

AU$0.00(0.00%)

At close: Jan 08 4:00 PM EST

AU$0.10

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.08 - AU$0.18

Previous CloseN/A

Volume246.69K

Average Volume (3M)1.10M

Market Cap

AU$67.07M

Enterprise ValueAU$62.91M

Total Cash (Recent Filing)AU$9.72M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.92

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding698,628,660

10 Day Avg. Volume1,596,000

30 Day Avg. Volume1,096,098

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)25.24

Price to Sales (P/S)0.00

P/FCF Ratio-4.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.28

Price Target Upside180.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Zero DebtThe company carries no reported debt, removing interest and refinancing burdens and preserving operational flexibility. Over a multi-month horizon this reduces immediate solvency pressure and gives management optionality for fundraising or strategic partnerships despite other capital constraints.

Specialized Veterinary FocusA clear niche in animal health and veterinary therapeutics creates a focused business model with durable demand drivers (pet ownership, livestock health). Regulatory complexity and product specialization can create barriers to entry and allow sustained commercial opportunities if clinical and approval progress resumes.

Cash Flow TransparencyOperating cash flows move consistently with reported losses, indicating limited distortion from working-capital timing. That alignment improves predictability for financing needs and allows more reliable runway modelling, which supports durable planning for R&D and commercial milestones.

Bears Say

Revenue Collapse To ZeroLoss of all reported revenue signals a severe deterioration in commercial traction and raises structural questions about product market fit and distribution. Without restored sales, the company cannot generate sustainable cash flows, increasing reliance on external funding and imperilling long-term viability.

Accelerating Cash BurnRapidly widening operating cash outflows materially shorten runway and increase the likelihood of additional capital raises. Given limited internal cash generation, persistent negative OCF constrains R&D, regulatory submissions, and commercialization activities, and raises dilution and financing-risk concerns.

Sharp Equity ErosionSteep decline in shareholders' equity reduces the capital buffer available to absorb losses or fund development. Even with zero debt, depleted equity limits strategic flexibility, increases vulnerability to adverse outcomes, and elevates the probability of dilutive financing or cutbacks in core programs.

Pharmaust Limited News

Neurizon Expands NUZ-001 Huntington’s Disease Data at ASENT 2026

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an update. Neurizon Therapeutics has presented new preclinical data on its...

10d ago

Neurizon Therapeutics Options Lapse, Trimming Potential Equity Overhang

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics Limited has informed the market...

11d ago

Neurizon Draws First $5m Tranche to Advance ALS Drug Trial

Pharmaust Limited ( ($AU:NUZ) ) has shared an update. Neurizon Therapeutics has drawn down the first $5 million...

16d ago

Neurizon Taps A$5m in Convertible Note Funding From Obsidian

Pharmaust Limited ( ($AU:NUZ) ) has issued an announcement. Neurizon Therapeutics has issued a cleansing notice ahead of...

16d ago

Neurizon issues 10m shares under convertible note, affirms compliance and disclosure

Pharmaust Limited ( ($AU:NUZ) ) has provided an update. Neurizon Therapeutics has issued 10,000,000 fully paid ordinary shares...

16d ago

Neurizon Begins Pivotal NUZ-001 Dosing in HEALEY ALS Platform Trial

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an update. Neurizon Therapeutics has begun dosing the first participant with...

17d ago

Neurizon Narrows Half-Year Loss as Other Income Jumps and Net Assets Strengthen

Pharmaust Limited ( ($AU:NUZ) ) has issued an announcement. Neurizon Therapeutics Limited reported a sharply lower half-year loss...

18d ago

Neurizon Publishes General Meeting Results and Enhances Investor Engagement

The latest update is out from Pharmaust Limited ( ($AU:NUZ) ). Neurizon Therapeutics Limited has released the results...

23d ago

Neurizon Therapeutics Issues Heavily Qualified General Meeting Presentation

An announcement from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics has released a general meeting...

23d ago

Neurizon Therapeutics Director Marcus Hughes Increases Shareholding

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an announcement. Neurizon Therapeutics director Marcus Hughes has increased his equity...

1M ago

NUZ FAQ

What was Pharmaust Limited’s price range in the past 12 months?

Pharmaust Limited lowest share price was AU$0.08 and its highest was AU$0.18 in the past 12 months.

What is Pharmaust Limited’s market cap?

Pharmaust Limited’s market cap is AU$67.07M.

When is Pharmaust Limited’s upcoming earnings report date?

Pharmaust Limited’s upcoming earnings report date is Aug 28, 2026 which is in 166 days.

How were Pharmaust Limited’s earnings last quarter?

Pharmaust Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.

Is Pharmaust Limited overvalued?

According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharmaust Limited pay dividends?

Pharmaust Limited does not currently pay dividends.

What is Pharmaust Limited’s EPS estimate?

Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaust Limited have?

Pharmaust Limited has 698,628,660 shares outstanding.

What happened to Pharmaust Limited’s price movement after its last earnings report?

Pharmaust Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.031%.

Which hedge fund is a major shareholder of Pharmaust Limited?

Currently, no hedge funds are holding shares in AU:NUZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharmaust Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

-247.98%

Trailing 12-Months

Asset Growth

-64.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharmaust Limited

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Pharmaust Limited (NUZ) Earnings & Revenues

Historic Earnings Reports

NUZ Stock 12 Month Forecast

Average Price Target

AU$0.28

▲(180.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"May<br/>2025","9":"Oct<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.09,0.10461538461538461,0.11923076923076922,0.13384615384615384,0.14846153846153848,0.16307692307692306,0.1776923076923077,0.19230769230769232,0.20692307692307693,0.22153846153846155,0.23615384615384616,0.25076923076923074,0.26538461538461544,{"y":0.28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.09,0.10461538461538461,0.11923076923076922,0.13384615384615384,0.14846153846153848,0.16307692307692306,0.1776923076923077,0.19230769230769232,0.20692307692307693,0.22153846153846155,0.23615384615384616,0.25076923076923074,0.26538461538461544,{"y":0.28,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.09,0.10461538461538461,0.11923076923076922,0.13384615384615384,0.14846153846153848,0.16307692307692306,0.1776923076923077,0.19230769230769232,0.20692307692307693,0.22153846153846155,0.23615384615384616,0.25076923076923074,0.26538461538461544,{"y":0.28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.191,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.191,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.191,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.172,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.122,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.132,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.117,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.152,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.167,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.122,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.085,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.09,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.09,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >